TIDMERGO

RNS Number : 1468X

Ergomed plc

25 August 2022

PRESS RELEASE

Notice of Interim Results

Guildford, UK - 25 August 2022: Ergomed plc, (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, will announce its interim results for the six months ending 30 June 2022 on 27 September 2022.

Miroslav Reljanović, Executive Chairman, Richard Barfield, Chief Financial Officer, and Keith Byrne, Senior Vice-President, Capital Markets & Strategy, will host an in-person briefing for analysts at 9.30am BST on the day of the results at the offices of Numis, 45 Gresham St, London EC2V 7BF. There will also be a live webcast and conference call with a Q&A session. The webcast will be shared on the Investor Portal section of the Company's website at www.ergomedplc.com .

ENDS

Enquiries:

 
 Ergomed plc                                                     Tel: +44 (0) 1483 402 
                                                                                   975 
 Miroslav Reljanović (Executive Chairman) 
 Richard Barfield (Chief Financial Officer) 
  Keith Byrne (Senior Vice-President, Capital 
  Markets & Strategy) 
 
 Numis (Nominated Advisor and Joint Broker)                  Tel: +44 (0) 20 7260 1000 
 Freddie Barnfield / Euan Brown (Nominated 
  Adviser) 
 James Black (Broker) 
 
   Peel Hunt LLP (Joint Broker)                                   Tel: +44 (0) 20 7418 
   James Steel / Dr Christopher Golden                                            8900 
 Consilium Strategic Communications - for                    Tel: +44 (0) 20 3709 5700 
  UK enquiries 
 Chris Gardner / Matthew Neal                              ergomed@consilium-comms.com 
 Angela Gray

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO) and mission-critical regulatory compliance and consulting services under the ADAMAS brand. For further information, visit: http://ergomedplc.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORDBGDIIGDDGDS

(END) Dow Jones Newswires

August 25, 2022 02:00 ET (06:00 GMT)

Ergomed (LSE:ERGO)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas Ergomed.
Ergomed (LSE:ERGO)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas Ergomed.